Masanori Matsumoto

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 29

Top Topics

Hodgkin Lymphoma

Top Venues

International journal of hematology

Journal of thrombosis and haemostasis : JTH

This page only lists publications with an associated author ORCID identifier.

Publications

Kenki Saito, Kazuya Sakai, Masayuki Kubo, Hidekazu Azumi, Atsushi Hamamura, Shinichi Ochi, Hiroki Amagase, Hisako Kunieda, Yoshiyuki Ogawa, Hideo Yagi, Masanori Matsumoto
Persistent ADAMTS13 Inhibitor Delays Recovery of ADAMTS13 activity in Caplacizumab-Treated Japanese iTTP Patients. Blood advances (2024)
Kenki Saito, Kazuya Sakai, Masayuki Kubo, Hidekazu Azumi, Atsushi Hamamura, Shinichi Ochi, Hiroki Amagase, Hisako Kunieda, Yoshiyuki Ogawa, Hideo Yagi, Masanori Matsumoto
Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP. Blood advances 8 (9) (2024)
Masahito Uchihara, Kazuya Sakai, Koki Shibata, Kenki Saito, Bernhard Lämmle, Masanori Matsumoto
Immune-mediated thrombotic thrombocytopenic purpura with ischaemic cerebral infarction preceding onset of thrombocytopenia and microangiopathic haemolytic anaemia: A case report. British journal of haematology (2024)
Kenki Saito, Kazuya Sakai, Masayuki Kubo, Hidekazu Azumi, Atsushi Hamamura, Shinichi Ochi, Hiroki Amagase, Hisako Kunieda, Yoshiyuki Ogawa, Hideo Yagi, Masanori Matsumoto
Persistent ADAMTS13 Inhibitor Delays Recovery of ADAMTS13 activity in Caplacizumab-Treated Japanese iTTP Patients. Blood advances (2024)
Kenki Saito, Kazuya Sakai, Masayuki Kubo, Hidekazu Azumi, Atsushi Hamamura, Shinichi Ochi, Hiroki Amagase, Hisako Kunieda, Yoshiyuki Ogawa, Hideo Yagi, Masanori Matsumoto
Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP. Blood advances 8 (9) (2024)
Kenki Saito, Kazuya Sakai, Masayuki Kubo, Hidekazu Azumi, Atsushi Hamamura, Shinichi Ochi, Hiroki Amagase, Hisako Kunieda, Yoshiyuki Ogawa, Hideo Yagi, Masanori Matsumoto
Persistent ADAMTS13 Inhibitor Delays Recovery of ADAMTS13 activity in Caplacizumab-Treated Japanese iTTP Patients. Blood advances (2024)
Kenki Saito, Kazuya Sakai, Masayuki Kubo, Hidekazu Azumi, Atsushi Hamamura, Shinichi Ochi, Hiroki Amagase, Hisako Kunieda, Yoshiyuki Ogawa, Hideo Yagi, Masanori Matsumoto
Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP. Blood advances 8 (9) (2024)
Masayuki Kubo, Masanori Matsumoto
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura. International journal of hematology 117 (3) (2023)
Masanori Matsumoto, Yoshitaka Miyakawa, Koichi Kokame, Yasunori Ueda, Hideo Wada, Satoshi Higasa, Hideo Yagi, Yoshiyuki Ogawa, Kazuya Sakai, Toshiyuki Miyata, Eriko Morishita, Yoshihiro Fujimura, null null
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023. International journal of hematology (2023)
Hiroaki Takaya, Tadashi Namisaki, Masahide Enomoto, Takahiro Kubo, Yuki Tsuji, Yukihisa Fujinaga, Norihisa Nishimura, Kosuke Kaji, Hideto Kawaratani, Kei Moriya, Takemi Akahane, Masanori Matsumoto, Hitoshi Yoshiji
The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure. Biology 12 (2) (2023)
Masayuki Kubo, Masanori Matsumoto
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura. International journal of hematology 117 (3) (2023)
Hiroaki Takaya, Tadashi Namisaki, Masahide Enomoto, Takahiro Kubo, Yuki Tsuji, Yukihisa Fujinaga, Norihisa Nishimura, Kosuke Kaji, Hideto Kawaratani, Kei Moriya, Takemi Akahane, Masanori Matsumoto, Hitoshi Yoshiji
The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure. Biology 12 (2) (2023)
Masayuki Kubo, Masanori Matsumoto
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura. International journal of hematology 117 (3) (2023)
Masayuki Kubo, Masanori Matsumoto
Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura. International journal of hematology (2023)
Yoshitaka Miyakawa, Kazunori Imada, Satoshi Ichikawa, Hitoji Uchiyama, Yasunori Ueda, Akihito Yonezawa, Shigeki Fujitani, Yoshiyuki Ogawa, Tadashi Matsushita, Hidesaku Asakura, Kenji Nishio, Kodai Suzuki, Yasuhiro Hashimoto, Hidenori Murakami, Sayaka Tahara, Tomoyuki Tanaka, Masanori Matsumoto
The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study. International journal of hematology (2022)
Erika Tarasco, Anne Sophie von Krogh, Radomira Hrdlickova, Thomas R Braschler, Teresa Iwaniec, Paul N Knöbl, Eriko Nakamura, Oleg Pikovsky, Stefan Farese, Odit Gutwein, Petr Kessler, Nina H Schultz, Charis von Auer, Jerzy Windyga, Kenneth Friedman, Ingrid Hrachovinova, James N George, Masanori Matsumoto, Reinhard Schneppenheim, Bernhard Lämmle, Johanna A Kremer Hovinga
Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease. Research and practice in thrombosis and haemostasis 6 (7) (2022)
Eriko Hamada, Kazuya Sakai, Shinya Yamada, Masayuki Kubo, Masaki Hayakawa, Masanori Matsumoto
No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey. Annals of hematology 101 (5) (2022)
Kazuya Sakai, Masanori Matsumoto, Laure de Waele, Charlotte Dekimpe, Eriko Nakamura, Masayuki Kubo, Claudia Tersteeg, Simon F De Meyer, Karen Vanhoorelbeke
ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura. Blood advances (2022)
Hiroshi Azuma, Toraji Amano, Naoya Kamiyama, Naofumi Takehara, Maki Jingu, Harumi Takagi, Osamu Sugita, Naoko Kobayashi, Tomoko Kure, Taro Shimizu, Tatsuhiro Ishida, Masanori Matsumoto, Hiromi Sakai
First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative. Blood advances 6 (21) (2022)
Masayuki Kubo, Kazuya Sakai, Masaki Hayakawa, Hirokazu Kashiwagi, Hideo Yagi, Yoshinobu Seki, Atsushi Hasegawa, Haruyuki Tanaka, Itsuto Amano, Yoshiaki Tomiyama, Masanori Matsumoto
Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia. Journal of thrombosis and haemostasis : JTH 20 (7) (2022)
Kaori Uchino, Kazuya Sakai, Saki Shinohara, Akifumi Matsuhisa, Yusuke Iida, Yuta Nakano, Saori Matsumura, Jo Kanasugi, Soichi Takasugi, Ayano Nakamura, Tomohiro Horio, Satsuki Murakami, Shohei Mizuno, Hidesuke Yamamoto, Ichiro Hanamura, Masanori Matsumoto, Akiyoshi Takami
Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature. International journal of hematology 116 (2) (2022)
Kazuya Sakai, Yoshihiro Fujimura, Toshiyuki Miyata, Ayami Isonishi, Koichi Kokame, Masanori Matsumoto
Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort. British journal of haematology 194 (2) (2021)
Erika Tarasco, Lukas Bütikofer, Kenneth D Friedman, James N George, Ingrid Hrachovinova, Paul N Knöbl, Masanori Matsumoto, Anne Sophie von Krogh, Isabella Aebi-Huber, Zuzana Cermakova, Magdalena Górska-Kosicka, Katarzyna Aleksandra Jalowiec, Carlo R Largiadèr, Zoltán Proházka, György Sinkovits, Jerzy Windyga, Bernhard Lämmle, Johanna A Kremer Hovinga
Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood 137 (25) (2021)
Michinori Kayashima, Kazuya Sakai, Kazuki Harada, Jun Kanetake, Masayuki Kubo, Eriko Hamada, Masaki Hayakawa, Kinta Hatakeyama, Masanori Matsumoto
Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura. International journal of hematology 114 (4) (2021)
Kazuya Sakai, Yoshihiro Fujimura, Yasuyuki Nagata, Satoshi Higasa, Masato Moriyama, Ayami Isonishi, Mutsuko Konno, Michiko Kajiwara, Yoshiyuki Ogawa, Shigehiko Kaburagi, Tomoko Hara, Koichi Kokame, Toshiyuki Miyata, Kinta Hatakeyama, Masanori Matsumoto
Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis : JTH 18 (11) (2020)
Kazuya Sakai, Hideo Wada, Yuki Nakatsuka, Masayuki Kubo, Masaki Hayakawa, Masanori Matsumoto
Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired Thrombotic Thrombocytopenic Purpura. Journal of intensive care medicine 36 (4) (2020)
Saori Tanabe, Yoshihiro Fujimura, Bernhard Lämmle, Toshiyuki Kimura, Ayami Isonishi, Kazuya Sakai, Masanori Matsumoto
Stealth thrombosis of brain and kidney in a girl with Upshaw-Schulman syndrome not receiving prophylactic plasma infusions. International journal of hematology 112 (5) (2020)
Masayuki Kubo, Kazuya Sakai, Yumi Yoshii, Masaki Hayakawa, Masanori Matsumoto
Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan. International journal of hematology 112 (6) (2020)
Yoko Yoshida, Masanori Matsumoto, Hideo Yagi, Ayami Isonishi, Kazuya Sakai, Masaki Hayakawa, Yuji Hori, Toshiyuki Sado, Hiroshi Kobayashi, Yoshihiro Fujimura
Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome. Blood advances 1 (20) (2017)